News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Accepts Filing of New Drug Application (NDA) for Yaupon Therapeutics Inc.'s Proprietary Gel Formulation of Mechlorethamine Hydrochloride



10/4/2011 8:46:14 AM

MALVERN, Pa.--(BUSINESS WIRE)--Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine). Yaupon is seeking U.S. marketing approval of its mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of Cutaneous T-Cell Lymphoma (CTCL).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES